Inactive Instrument

AKOUOS

AKUS

US00973J1016

Biotechnology & Medical Research

Akouos, Inc.(NasdaqGS:AKUS) dropped from Russell 2000 Growth Index

June 25, 2021 at 12:00 am EDT

Latest news about AKOUOS

Akouos, Inc. Announces Positive Initial Clinical Results from the Phase 1/2 AK-OTOF-101 Study	Jan. 23	CI
Akouos, Inc. Announces Executive and Board Changes	22-12-01	CI
Lilly Wraps Up Acquisition of Akouos	22-12-01	MT
Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Composite Index	22-12-01	CI
Eli Lilly and Company completed the acquisition of Akouos, Inc. from a group of shareholders.	22-11-30	CI
Eli Lilly's Buyout Offer Accepted by 81% Akouos Shareholders at Closing	22-11-30	MT
Akouos, Inc.(NasdaqGS:AKUS) dropped from S&P TMI Index	22-11-30	CI
Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Biotechnology Index	22-11-29	CI
Akouos Q3 Loss Narrows	22-11-14	MT
Akouos, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
North American Morning Briefing : Fed Hopes, China -2-	22-11-11	DJ
Piper Sandler Downgrades Akouos to Neutral From Overweight, Adjusts Price Target to $13 From $18	22-10-19	MT
William Blair Downgrades Akouos to Market Perform From Outperform	22-10-19	MT
Health Care Up Amid Earnings, Deals -- Health Care Roundup	22-10-18	DJ
Sector Update: Healthcare Stocks Nudging Higher Near Tuesday's Close	22-10-18	MT
Eli Lilly to Acquire Genetic Medicine Developer Akouos for up to $610 Million	22-10-18	MT
Sector Update: Health Care Stocks Advancing in Choppy Session Tuesday Afternoon	22-10-18	MT
Top Midday Gainers	22-10-18	MT
Sector Update: Health Care	22-10-18	MT
HC Wainwright Downgrades Akouos to Neutral from Buy	22-10-18	MT
Eli Lilly to Acquire Genetic Medicine Firm Akouos for Up to $610 Million	22-10-18	MT
Akouos Shares Soar on Takeover by Eli Lilly	22-10-18	DJ
Sector Update: Health Care Stocks Advance Premarket Tuesday	22-10-18	MT
Sector Update: Health Care	22-10-18	MT
ETF Preview: ETFs, Futures Climb Pre-Bell Ahead of Industrial Production Report	22-10-18	MT

Akouos Inc. precision genetic medicine company focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals. The Company is focused on developing precision therapies for forms of sensorineural hearing loss. The Company's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The Company is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.84%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-9.28%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs

AKOUOS

Equities

AKUS

US00973J1016

Biotechnology & Medical Research

Akouos, Inc.(NasdaqGS:AKUS) dropped from Russell 2000 Growth Index

Latest news about AKOUOS

Chart AKOUOS

Company Profile

Sector Bio Therapeutic Drugs